Purple Biotech (PPBT)
(Delayed Data from NSDQ)
$6.98 USD
-0.12 (-1.69%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $6.80 -0.18 (-2.58%) 7:02 PM ET
2-Buy of 5 2
F Value C Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Purple Biotech Ltd Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 15 | 32 | 47 | 58 | 6 |
Receivables | 0 | 1 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 1 | 1 | 2 |
Total Current Assets | 16 | 33 | 48 | 59 | 8 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 28 | 21 | 20 | 20 | 6 |
Deposits & Other Assets | 0 | 0 | 0 | 3 | 0 |
Total Assets | 44 | 55 | 70 | 84 | 15 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 5 | 3 | 2 | 2 |
Total Current Liabilities | 7 | 7 | 4 | 3 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10 | 8 | 5 | 4 | 4 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 133 | 126 | 124 | 119 | 47 |
Retained Earnings | -137 | -118 | -96 | -78 | -50 |
Other Equity | 39 | 38 | 37 | 38 | 13 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 34 | 47 | 65 | 80 | 11 |
Total Liabilities & Shareholder's Equity | 44 | 55 | 70 | 84 | 15 |
Total Common Equity | 34 | 47 | 65 | 80 | 11 |
Shares Outstanding | 25.20 | 18.40 | 25.90 | 15.70 | 1.90 |
Book Value Per Share | 1.36 | 2.56 | 2.51 | 5.08 | 5.72 |
Fiscal Year End for Purple Biotech Ltd Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 7 | 11 | 15 | 16 | 18 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 0 | 1 | 1 |
Total Current Assets | 8 | 11 | 16 | 17 | 19 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 28 | 28 | 28 | 28 | 28 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 36 | 40 | 44 | 45 | 48 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 4 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 5 | 3 | 3 | 3 |
Total Current Liabilities | 6 | 9 | 7 | 6 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 3 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 7 | 9 | 10 | 7 | 5 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 136 | 134 | 133 | 133 | 132 |
Retained Earnings | -144 | -141 | -137 | -133 | -128 |
Other Equity | 37 | 39 | 39 | 38 | 38 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 29 | 31 | 34 | 39 | 43 |
Total Liabilities & Shareholder's Equity | 36 | 40 | 44 | 45 | 48 |
Total Common Equity | 29 | 31 | 34 | 39 | 43 |
Shares Outstanding | 25.20 | 25.20 | 25.20 | 22.00 | 20.80 |
Book Value Per Share | 1.17 | 1.23 | 1.36 | 1.76 | 2.06 |